12 unknown. 12 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Unknown 12 |
| Phase 2 | 3 | Unknown 3 |
Follow Psoriasis: new trials by email Literature Review of Psoriasis trials Research Report on Psoriasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Ixekizumab in Patients with Refractory Guttate Psoriasis Ixekizumab - Guttate Psoriasis | Phase 2 / Phase 3 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 50 | 2025-05-01 | 2025-02-10 |
| Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis HB0034 - Generalized Pustular Psoriasis | Phase 2 / Phase 3 | Unknown | Shanghai Huaota Biopharmaceutical Co., Ltd. | 33 | 2024-09-02 | 2025-02-14 |
| A Study to Evaluate the Efficacy and Safety of LZM012 LZM012, Secukinumab - Psoriasis | Phase 3 | Unknown | Livzon Pharmaceutical Group Inc. | 918 | 2023-08-21 | 2023-11-01 |
| Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis Prednisolone, Sulfasalazine, Leflunomide - Psoriatic Arthritis, Withdrawal | Phase 3 | Unknown | University of Erlangen-Nürnberg Medical School | 270 | 2020-10-19 | 2022-11-14 |
| The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis SCT630, Adalimumab - Psoriasis | Phase 3 | Unknown | Sinocelltech Ltd. | 330 | 2019-09-05 | 2021-01-29 |
| Turmeric Based Therapy in the Treatment of Psoriasis: A Clinical Trial Turmeric Extract, Turmeric Extract in Olive oil, Petrolatum - Psoriasis | Phase 2 / Phase 3 | Unknown | Zagazig University | 50 | 2019-09-01 | 2019-08-28 |
| Assessment of the Clinical and Ultrasound Response to Apremilast by Clinical Evaluation and by a Joint-periarticular-nail Ultrasound Index in Patients With Active Psoriatic Arthritis Apremilast - Arthritis; Psoriasis (Etiology) | Phase 3 | Unknown | Hospital Universitari Vall d'Hebron Research Institute | 56 | 2017-11-02 | 2017-10-17 |
| Assessing the Efficacy and Safety of Metformin in Treatment of Moderate Psoriasis Metformin, Placebo, Topical Coal tar - Psoriasis | Phase 3 | Unknown | Post Graduate Institute of Medical Education and Research, Chandigarh | 40 | 2016-01-01 | 2016-01-01 |
| Safety and Efficacy Study of Etanercept (Qiangke®) to Treat Moderate to Severe Plaque Psoriasis etanercept, etanercept (half dose), placebo - Plaque Psoriasis, Psoriasis | Phase 3 | Unknown | Shanghai Celgen Bio-Pharmaceutical Co.,Ltd | 216 | 2015-01-01 | 2016-03-08 |
| The Effect of Alga Dunaliella Bardawil on Psoriasis Alga Dunaliella Bardawil placebo, Dunaliella Bardawil - Psoriasis | Phase 3 | Unknown | Sheba Medical Center | 46 | 2012-06-01 | 2012-06-26 |
| Psoriasis and Climate Therapy- Effect of Motivational Follow- up Calls on Clinical and Health Economic Parameters Motivational interviewing - Psoriasis | Phase 3 | Unknown | Oslo University Hospital | 169 | 2011-09-01 | 2015-05-29 |
| Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in Cortisosensitive Dermatosis 0.5% prednisolone acetate cream, 0.1% betamethasone valerate cream - Dermatitis, Atopic, Dermatitis, Contact | Phase 3 | Unknown | Mantecorp Industria Quimica e Farmaceutica Ltd. | 170 | 2010-02-01 | 2009-11-11 |
Arthritis (1) · Arthritis, Psoriatic (1) · Dermatitis, Atopic (1) · Dermatitis, Contact (1) · Dermatitis, Seborrheic (1) · Guttate Psoriasis (1) · Skin Diseases (1)
Skin Diseases, Papulosquamous (12) · Skin and Connective Tissue Diseases (12) · Skin Diseases (11) · Joint Diseases (2) · Musculoskeletal Diseases (2) · Arthritis (1) · Bone Diseases (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Dermatitis (1) · Genetic Diseases, Inborn (1) · Hypersensitivity (1) · Hypersensitivity, Immediate (1) · Immune System Diseases (1) · Sebaceous Gland Diseases (1)
Adalimumab (2) · Etanercept (2) · apremilast (2) · calcipotriene (2) · ixekizumab (2) · secukinumab (2) · Abatacept (1) · Betamethasone (1) · Cbr protein, Dunaliella (1) · Certolizumab Pegol (1) · Coal Tar (1) · Infliximab (1) · Leflunomide (1) · Metformin (1) · Methotrexate (1)
Hospital Universitari Vall d'Hebron Research Institute (1) · Livzon Pharmaceutical Group Inc. (1) · Mantecorp Industria Quimica e Farmaceutica Ltd. (1) · Oslo University Hospital (1) · Post Graduate Institute of Medical Education and Research, Chandigarh (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Shanghai Celgen Bio-Pharmaceutical Co.,Ltd (1) · Shanghai Huaota Biopharmaceutical Co., Ltd. (1) · Sheba Medical Center (1) · Sinocelltech Ltd. (1) · University of Erlangen-Nürnberg Medical School (1) · Zagazig University (1)
China (4) · Germany (1) · Israel (1) · Norway (1)
Adilson Costa, MD (1) · Astrid K. Wahl, PhD (1) · Hagar Nofal (1) · Hongzhong Jin, M.D. (1) · Jianzhong Zhang, PhD (1) · Roberta F. J. Criado, MD (1) · Shoshana Greenberg, MD (1) · Sunil Dogra, MD (1)
PMID 14627786, PMID 15948997, PMID 20124563, PMID 22348620, PMID 24790410